HealthEquity, Inc. Expected to Earn Q3 2025 Earnings of $0.53 Per Share (NASDAQ:HQY)

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Zacks Research raised their Q3 2025 earnings estimates for shares of HealthEquity in a report issued on Tuesday, April 9th. Zacks Research analyst R. Department now anticipates that the company will earn $0.53 per share for the quarter, up from their prior forecast of $0.48. The consensus estimate for HealthEquity's current full-year earnings is $2.11 per share. Zacks Research also issued estimates for HealthEquity's FY2027 earnings at $3.69 EPS.

Several other brokerages have also issued reports on HQY. Barrington Research reaffirmed an "outperform" rating and issued a $100.00 target price on shares of HealthEquity in a research note on Friday, March 22nd. JPMorgan Chase & Co. raised their target price on shares of HealthEquity from $86.00 to $108.00 and gave the company an "overweight" rating in a research note on Tuesday, April 2nd. KeyCorp increased their price target on shares of HealthEquity from $85.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, March 22nd. Royal Bank of Canada increased their price target on shares of HealthEquity from $90.00 to $92.00 and gave the company an "outperform" rating in a research report on Wednesday, March 20th. Finally, BTIG Research increased their price target on shares of HealthEquity from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $96.17.

HealthEquity Trading Up 3.4 %

Shares of NASDAQ HQY traded up $2.69 during mid-day trading on Wednesday, hitting $81.30. The company's stock had a trading volume of 759,854 shares, compared to its average volume of 612,192. The stock has a market cap of $6.98 billion, a price-to-earnings ratio of 127.03, a price-to-earnings-growth ratio of 1.30 and a beta of 0.53. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76. HealthEquity has a one year low of $48.86 and a one year high of $84.49. The company's fifty day simple moving average is $80.69 and its 200-day simple moving average is $73.96.

Insider Activity

In other news, CEO Jon Kessler sold 33,765 shares of HealthEquity stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the sale, the chief executive officer now directly owns 126,635 shares in the company, valued at $10,106,739.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Jon Kessler sold 33,765 shares of the firm's stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the completion of the transaction, the chief executive officer now directly owns 126,635 shares of the company's stock, valued at $10,106,739.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Evelyn S. Dilsaver sold 32,500 shares of the firm's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the completion of the transaction, the director now directly owns 32,123 shares of the company's stock, valued at $2,547,032.67. The disclosure for this sale can be found here. Insiders have sold 71,322 shares of company stock worth $5,682,895 over the last ninety days. Insiders own 2.70% of the company's stock.

Hedge Funds Weigh In On HealthEquity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rise Advisors LLC bought a new stake in shares of HealthEquity in the first quarter valued at about $28,000. Cape Investment Advisory Inc. bought a new stake in shares of HealthEquity in the fourth quarter valued at about $27,000. McGlone Suttner Wealth Management Inc. bought a new stake in shares of HealthEquity in the fourth quarter valued at about $29,000. DekaBank Deutsche Girozentrale bought a new stake in shares of HealthEquity in the third quarter valued at about $41,000. Finally, Lazard Asset Management LLC boosted its position in shares of HealthEquity by 117.9% in the third quarter. Lazard Asset Management LLC now owns 549 shares of the company's stock valued at $40,000 after acquiring an additional 297 shares during the period. 99.55% of the stock is owned by institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.